Nectar Lifesci.

{
  "main_header": {
    "sid": 216478,
    "name": "Nectar Lifesci.",
    "stock_name": "Nectar Lifesci.",
    "full_name": "Nectar Lifescience Ltd",
    "name_url": "stocks-analysis/nectar-lifesci",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "13.92",
    "chg": -0.01,
    "chgp": "-0.07%",
    "dir": -1,
    "prev_price": "13.93",
    "mcapval": "272.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532649,
    "symbol": "NECLIFE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE023H01027",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "3.38 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nectar-lifesci-216478-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nectar Lifescience Ltd Stock Hits 52-Week Low Amidst Continued Financial Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-stock-hits-52-week-low-amidst-continued-financial-struggles-3814291",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/NectarLifescien_priceRelatedfactors_3814291.png",
        "date": "2026-02-01 10:41:53",
        "description": "Nectar Lifescience Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.13.18 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics."
      },
      {
        "title": "Nectar Lifescience Declines 3.87%: Circuit Limits and Operational Woes Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-declines-387-circuit-limits-and-operational-woes-shape-the-week-3804235",
        "imagepath": "",
        "date": "2026-01-25 13:01:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Lower circuit hit amid heavy selling pressure (Rs.14.39)</p>\n                    <p><strong>Jan 22:</strong> Upper circuit surge on strong buying interest (Rs.14.58)</p>\n                    <p><strong>Jan 23:</strong> Q3 FY26 results reveal deepening operational losses</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.14.66 (-3.87%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.15.25</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.14.66</div><..."
      },
      {
        "title": "Nectar Lifescience Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-3804047",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NectarLifescien_mojoScore_3804047.png",
        "date": "2026-01-25 10:10:16",
        "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Are Nectar Lifescience Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nectar-lifescience-ltd-latest-results-good-or-bad-3803787",
        "imagepath": "",
        "date": "2026-01-24 19:13:10",
        "description": "Nectar Lifescience Ltd's latest financial results indicate significant operational challenges. For the quarter ended Q3 FY26, the company reported a consolidated net loss of ₹176.01 crores, which reflects a drastic year-on-year decline. Net sales were recorded at ₹5.71 crores, showing minimal change from the previous year but a substantial drop from ₹430.70 crores in Q4 FY25. This stark revenue contraction suggests serious disruptions in the company's operations.\n\nThe operating margin, excluding other income, stood at -6.60%, indicating that the company is unable to cover its basic operational expenses from its revenue. Although there was a slight sequential improvement from the previous quarter, the overall financial health remains precarious. The return on equity (ROE) was reported at -17.19%, highlighting inefficiencies in capital utilization.\n\nThe nine-month performance for FY26 also paints a troubling ..."
      },
      {
        "title": "Are Nectar Lifescience Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-nectar-lifescience-ltd-latest-results-good-or-bad-3802415",
        "imagepath": "",
        "date": "2026-01-23 19:14:05",
        "description": "Nectar Lifescience Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹176.01 crores, which marks a substantial deterioration compared to the previous quarter's loss of ₹63.23 crores. This indicates a widening of losses, reflecting ongoing financial distress.\n\nRevenue generation has sharply declined, with net sales plummeting to ₹5.71 crores from ₹430.70 crores in the prior quarter, representing a staggering 98.78% sequential drop. This collapse in revenue generation suggests severe operational disruptions or potential issues within the business model. Year-on-year, the sales figures show a slight decline of 0.52%, but this is overshadowed by the drastic quarterly changes.\n\nThe operating margin turned negative at -6.60%, a stark contrast to the positive margin of 11.09% recorded in the same quarter last year. This shift indic..."
      },
      {
        "title": "Nectar Lifescience Q3 FY26: Operational Crisis Deepens as Losses Mount",
        "link": "https://www.marketsmojo.com/news/result-analysis/nectar-lifescience-q3-fy26-operational-crisis-deepens-as-losses-mount-3802401",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NectarLifescien_quaterlyResult_3802401.png",
        "date": "2026-01-23 18:45:38",
        "description": "Nectar Lifescience Ltd., a Mohali-based pharmaceutical company specialising in cephalosporins, continues to grapple with severe operational challenges as its financial performance deteriorates across key metrics. The micro-cap company, with a market capitalisation of ₹290.00 crores, reported a consolidated net loss of ₹176.01 crores in Q3 FY26, marking a staggering 3,143.04% decline year-on-year from a profit of ₹5.60 crores in Q3 FY25. The stock, currently trading at ₹14.77, has plunged 62.47% over the past year, vastly underperforming both the broader market and its pharmaceutical sector peers."
      },
      {
        "title": "Nectar Lifescience Ltd Surges to Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-surges-to-upper-circuit-amid-strong-buying-pressure-3799703",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NectarLifescien_stocks_hitting_upper_circuit_3799703.png",
        "date": "2026-01-22 10:00:09",
        "description": "Nectar Lifescience Ltd surged to hit its upper circuit limit on 22 Jan 2026, registering a maximum daily gain of 4.98% as robust buying interest propelled the stock sharply higher. This marks a notable reversal after a prolonged downtrend, although the stock remains under pressure from its longer-term moving averages and a recent downgrade to a Strong Sell rating."
      },
      {
        "title": "Nectar Lifescience Ltd Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nectar-lifescience-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3794716",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NectarLifescien_stocks_hitting_lower_circuit_3794716.png",
        "date": "2026-01-19 15:00:08",
        "description": "Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 19 Jan 2026, culminating in the stock hitting its lower circuit limit. The share price plunged by 4.95% to close at ₹14.39, marking the maximum permissible daily loss and reflecting mounting investor concerns amid a sustained downtrend."
      },
      {
        "title": "Nectar Lifescience Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nectar-lifescience-ltd-is-rated-strong-sell-3791844",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/NectarLifescien_mojoScore_3791844.png",
        "date": "2026-01-14 10:10:21",
        "description": "Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      }
    ],
    "total": 572,
    "sid": "216478",
    "stock_news_url": "https://www.marketsmojo.com/news/nectar-lifescience-216478"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 10(7) of SEBI (SAST) Regulations 2011",
      "datetime": "30-Jan-2026",
      "details": "The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "29-Jan-2026",
      "details": "Please find attached herewith copy of newspaper publication about dispatch/ mailing of Postal Ballot Notice",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Notice of Postal Ballot",
      "datetime": "28-Jan-2026",
      "details": "Please find enclosed the Postal Ballot Notice together with the Explanatory Statement thereto seeking approval of the Members for Appointment of Mr. Sushil Kapoor as a Director of the Company liable to retire by rotation as well as Wholetime Director designated as Director (Finance) and to adopt the new set of memorandum of association with amended object clause of the Company and as set out in the said Notice. The Notice is also available on the website of the Company i.e. www.neclife.com/about-3-9 and website of KFin Technologies Limited at https://evoting.kfintech.com. Members whose names appeared in the Register of Members/ List of Beneficial Owners as on the cut-off date i.e. Friday January 23 2026 are eligible for the purpose of remote e-voting. The remote e-voting period shall commence on Friday January 30 2026 09:00 A.M (IST) and will end on Saturday February 28 2026 05:00 P.M. (IST). The results of the Postal Ballot will be announced on or before March 02 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has declared <strong>5%</strong> dividend, ex-date: 11 Sep 20",
          "dt": "2020-09-11",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Nectar Lifescience Ltd has announced <strong>1:10</strong> stock split, ex-date: 12 Nov 08",
          "dt": "2008-11-12",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nectar Lifescience Ltd Stock Hits 52-Week Low Amidst Continued Financial Struggles

2026-02-01 10:41:53

Nectar Lifescience Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.13.18 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics.

Read full news article

Nectar Lifescience Declines 3.87%: Circuit Limits and Operational Woes Shape the Week

2026-01-25 13:01:41

Key Events This Week

Jan 19: Lower circuit hit amid heavy selling pressure (Rs.14.39)

Jan 22: Upper circuit surge on strong buying interest (Rs.14.58)

Jan 23: Q3 FY26 results reveal deepening operational losses

Jan 23: Week closes at Rs.14.66 (-3.87%)

Week Open

Rs.15.25

Week Close

Rs.14.66

<...

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-01-25 10:10:16

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Are Nectar Lifescience Ltd latest results good or bad?

2026-01-24 19:13:10

Nectar Lifescience Ltd's latest financial results indicate significant operational challenges. For the quarter ended Q3 FY26, the company reported a consolidated net loss of ₹176.01 crores, which reflects a drastic year-on-year decline. Net sales were recorded at ₹5.71 crores, showing minimal change from the previous year but a substantial drop from ₹430.70 crores in Q4 FY25. This stark revenue contraction suggests serious disruptions in the company's operations. The operating margin, excluding other income, stood at -6.60%, indicating that the company is unable to cover its basic operational expenses from its revenue. Although there was a slight sequential improvement from the previous quarter, the overall financial health remains precarious. The return on equity (ROE) was reported at -17.19%, highlighting inefficiencies in capital utilization. The nine-month performance for FY26 also paints a troubling ...

Read full news article

Are Nectar Lifescience Ltd latest results good or bad?

2026-01-23 19:14:05

Nectar Lifescience Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported a consolidated net loss of ₹176.01 crores, which marks a substantial deterioration compared to the previous quarter's loss of ₹63.23 crores. This indicates a widening of losses, reflecting ongoing financial distress. Revenue generation has sharply declined, with net sales plummeting to ₹5.71 crores from ₹430.70 crores in the prior quarter, representing a staggering 98.78% sequential drop. This collapse in revenue generation suggests severe operational disruptions or potential issues within the business model. Year-on-year, the sales figures show a slight decline of 0.52%, but this is overshadowed by the drastic quarterly changes. The operating margin turned negative at -6.60%, a stark contrast to the positive margin of 11.09% recorded in the same quarter last year. This shift indic...

Read full news article

Nectar Lifescience Q3 FY26: Operational Crisis Deepens as Losses Mount

2026-01-23 18:45:38

Nectar Lifescience Ltd., a Mohali-based pharmaceutical company specialising in cephalosporins, continues to grapple with severe operational challenges as its financial performance deteriorates across key metrics. The micro-cap company, with a market capitalisation of ₹290.00 crores, reported a consolidated net loss of ₹176.01 crores in Q3 FY26, marking a staggering 3,143.04% decline year-on-year from a profit of ₹5.60 crores in Q3 FY25. The stock, currently trading at ₹14.77, has plunged 62.47% over the past year, vastly underperforming both the broader market and its pharmaceutical sector peers.

Read full news article

Nectar Lifescience Ltd Surges to Upper Circuit Amid Strong Buying Pressure

2026-01-22 10:00:09

Nectar Lifescience Ltd surged to hit its upper circuit limit on 22 Jan 2026, registering a maximum daily gain of 4.98% as robust buying interest propelled the stock sharply higher. This marks a notable reversal after a prolonged downtrend, although the stock remains under pressure from its longer-term moving averages and a recent downgrade to a Strong Sell rating.

Read full news article

Nectar Lifescience Ltd Hits Lower Circuit Amid Heavy Selling Pressure

2026-01-19 15:00:08

Nectar Lifescience Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 19 Jan 2026, culminating in the stock hitting its lower circuit limit. The share price plunged by 4.95% to close at ₹14.39, marking the maximum permissible daily loss and reflecting mounting investor concerns amid a sustained downtrend.

Read full news article

Nectar Lifescience Ltd is Rated Strong Sell

2026-01-14 10:10:21

Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

View All News